MMA
MDGL icon

Miracle Mile Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Miracle Mile Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-703
Closed -$368K – 1019
2026
Q1 		$368K Hold
703
– – 0.01% 666
2025
Q4 		$409K Hold
703
– – 0.01% 627
2025
Q3 		$322K Hold
703
– – ﹤0.01% 665
2025
Q2 		$213K Buy
703
+3
+0.4% +$894 ﹤0.01% 681
2025
Q1 		$232K Hold
700
– – ﹤0.01% 574
2024
Q4 		$216K Buy
+700
New +$197K ﹤0.01% 590
2023
Q1 		– Sell
-700
Closed -$203K – 530
2022
Q4 		$203K Buy
+700
New +$68.5K 0.01% 473

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Miracle Mile Advisors's MDGL Position: Q2 2026 in Review

Miracle Mile Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 703 shares — an estimated $368K sold.

Miracle Mile Advisors first reported a position in MDGL in Q4 2022 and held it in 7 quarters. The position peaked at $409K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Miracle Mile Advisors reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Miracle Mile Advisors sold 703 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $368K.
  • Miracle Mile Advisors first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • Miracle Mile Advisors's Madrigal Pharmaceuticals position peaked at $409K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Miracle Mile Advisors's 13F filing for Q2 2026, filed 22 Jul 2026.